Literature DB >> 2196552

Cardiovascular dopamine receptors: role of renal dopamine and dopamine receptors in sodium excretion.

M F Lokhandwala1, S S Hegde.   

Abstract

Research efforts in the area of peripheral dopamine have now established the presence of two distinct subtypes--DA1 and DA2--of DA receptors, and have identified a potential role for dopamine produced within the kidney in the control of renal sodium excretion. Selective DA1 and DA2 receptor agonists are being developed because they exhibit therapeutic potential for treatment of cardiovascular and renal disorders. Furthermore, basic research efforts are aimed towards identifying the stimulus and/or stimuli for the production of dopamine within the kidney and characterizing the cellular signalling processes involved in mediating the renal effects of dopamine and selective DA receptor agonists.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2196552     DOI: 10.1111/j.1600-0773.1990.tb00741.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  4 in total

1.  Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats.

Authors:  C Chen; M F Lokhandwala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

2.  Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule.

Authors:  H F Cheng; B N Becker; R C Harris
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

3.  The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  A H Altamirano-Espinoza; A González-Hernández; G Manrique-Maldonado; B A Marichal-Cancino; I Ruiz-Salinas; C M Villalón
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Dopamine DA-2 receptor sites in the rat renal cortex: a light microscope autoradiographic study.

Authors:  A Ricci; A Rossodivita; F Amenta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.